349 related articles for article (PubMed ID: 14661443)
1. [Meropenem therapy in children with febrile neutropenia].
Müller J; Kovács G; Garami M; Schmidt M; Fekete G
Orv Hetil; 2003 Oct; 144(43):2115-20. PubMed ID: 14661443
[TBL] [Abstract][Full Text] [Related]
2. Meropenem in the treatment of febrile neutropenic children.
Müller J; Garami M; Constantin T; Schmidt M; Fekete G; Kovács G
Pediatr Hematol Oncol; 2005 Jun; 22(4):277-84. PubMed ID: 16020114
[TBL] [Abstract][Full Text] [Related]
3. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
Fouyssac F; Salmon A; Mansuy L; Schmitt C; Bordigoni P; Chastagner P
Med Mal Infect; 2005 Jun; 35(6):357-62. PubMed ID: 15982848
[TBL] [Abstract][Full Text] [Related]
7. Meropenem monotherapy as an empirical treatment of febrile neutropenia in childhood cancer patients.
Erbey F; Bayram I; Yilmaz S; Tanyeli A
Asian Pac J Cancer Prev; 2010; 11(1):123-6. PubMed ID: 20593941
[TBL] [Abstract][Full Text] [Related]
8. Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital.
Roongpoovapatr P; Suankratay C
J Med Assoc Thai; 2010 Jul; 93(7):776-83. PubMed ID: 20649055
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.
Ram R; Farbman L; Leibovici L; Raanani P; Yeshurun M; Vidal L; Gafter-Gvili A; Peck A; Shpilberg O; Paul M
Int J Antimicrob Agents; 2012 Aug; 40(2):123-6. PubMed ID: 22727772
[TBL] [Abstract][Full Text] [Related]
10. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.
Bothra M; Seth R; Kapil A; Dwivedi SN; Bhatnagar S; Xess I
Indian J Pediatr; 2013 Apr; 80(4):297-302. PubMed ID: 23255077
[TBL] [Abstract][Full Text] [Related]
12. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
[TBL] [Abstract][Full Text] [Related]
13. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
14. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
Feld R; DePauw B; Berman S; Keating A; Ho W
J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
[TBL] [Abstract][Full Text] [Related]
15. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
16. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen.
J Antimicrob Chemother; 1995 Jul; 36(1):185-200. PubMed ID: 8537265
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes.
Jeddi R; Achour M; Amor RB; Aissaoui L; Bouterâa W; Kacem K; Lakhal RB; Abid HB; BelHadjAli Z; Turki A; Meddeb B
Hematology; 2010 Feb; 15(1):28-32. PubMed ID: 20132659
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer.
Pancharoen C; Mekmullica J; Buranachonapa J; Trongjit D; Nuchprayoon I; Vanichsetakul P; Seksarn P; Thisyakorn U
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S174-8. PubMed ID: 12929986
[TBL] [Abstract][Full Text] [Related]
20. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
